Research On Financial Risk Control Of Huarun Sanjiu's Merger And Acquisition Of Shenghuo Yaoye

In recent years,with the healthy and sustainable development of the national economy,people pay more attention to health,so the demand for related medical products is gradually expanding.As an important part of national economic growth,the pharmaceutical industry has been growing at a faster speed.Because of this,the M&a market of pharmaceutical enterprises is increasingly active.In 2018,although the capital market of China is facing contraction,the number of M&A transactions in the pharmaceutical industry has not been affected.In order to expand the market scale and complete the layout of the company's industrial chain,some large enterprises choose to accelerate the pace of M&A.However,with the rapid development of M&A,there are also corresponding M&A risks,which determine whether the M&A activities can succeed.Therefore,it is necessary to strengthen the research on the financial risk of M&A of pharmaceutical enterprises in the new situation.Based on the risk control method and risk aversion method,and on the basis of summarizing the research results of relevant scholars,this paper selects "Huarun Sanjiu M&A Shenghuo Yaoye" as a case study,combined with the current situation of M&A in the pharmaceutical industry,and studies the financial risks generated by the case.At the same time,in order to avoid the single and incomplete accuracy of the financial risk assessment method,this paper chooses the questionnaire survey party In this way,the risk assessment is carried out,and the financial risk generated by the M&A of Huarun Sanjiu is measured by the method of combining fuzzy comprehensive method and AHP.In order to test and predict the current and future effect of the merger,the paper analyzes the financial risk control measures taken before and after the completion of the merger,and evaluates and forecasts the effect of the merger by using the financial index analysis method and Z-value analysis method.Therefore,the research conclusions of this M&A are as follows:first,in terms of the financial risks generated by this M&A,during the whole M&A process,we should pay special attention to the valuation risk before the M&A and the integration risk after the M&A is completed;second,in terms of the enterprise development strategy,this M&A is successful and is playing a good synergy effect.Through the whole research and analysis of the merger and acquisition of Shenghuo Pharmaceutical Co.,Ltd.,this paper attempts to provide a complete financial risk control system for the pharmaceutical industry to predict the future financial risk of merger and acquisition,so as to play a substantive role in the financial risk control of the future merger and acquisition of pharmaceutical enterprises.